Condition: Ovarian Cancer · Triple-Negative Breast Cancer · Head and Neck Cancer · Sponsor: Institut Curie
SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer, advanced stage treatment-naïve cervical or vulva cancer and sarcoma (breast angiosarcoma and uterine sarcoma) cancers. This study will allowed to identify new molecular and/or immunological biomarkers associated with clinical and biological features of the tumors. All patients will receive standard treatment according to the stage of the diseases and usual procédures.
This description comes directly from the study's public registry record.
Anne-Sophie PLISSONNIER · 01 47 11 23 78 · drci.promotion@curie.fr
Always discuss trial participation with your own doctor first.
| Institut Bergonie | Bordeaux, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| Centre Leon Berard | Lyon, France | Recruiting |
| Institut Curie | Paris, France | Recruiting |
| Institut Curie Hopital Rene Huguenin | Saint-Cloud, France | Recruiting |
| Institut de Cancérologie de Lorraine - Nancy | Vandœuvre-lès-Nancy, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03017573